Covid-19
Update on the safety of COVID-19 Vaccine AstraZeneca
16 Mar, 2021 | 02:35h | UTCUpdate on the safety of COVID-19 Vaccine AstraZeneca
Related: Countries should continue AstraZeneca rollout: WHO – MedicalXpress AND Expert reaction to news that Germany has halted vaccinations with the Oxford-AstraZeneca COVID-19 vaccine – Science Media Centre AND AstraZeneca finds no evidence of increased blood clot risk from vaccine – Reuters AND Data suggest no increased risk of blood clots from the AstraZeneca vaccine. Australia shouldn’t pause its rollout – The Conversation
Commentary on Twitter
As of March 8th, Around 17 million people in the EU & UK received the vaccine , there have been 15 events of DVT & 22 events of pulmonary embolism reported among those given the vaccine,This is much lower than would be expected to occur naturally in a general population
Please RT https://t.co/tnn4brxwpp— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) March 14, 2021
B.1.1.7 variant linked to 55% higher mortality compared to other strains of SARS-CoV-2
16 Mar, 2021 | 02:32h | UTCOriginal study: Increased mortality in community-tested cases of SARS-CoV-2 lineage B.1.1.7 – Nature
Related: Death rate 64% higher with B117 COVID variant, study finds (study and commentary)
Commentary on Twitter (thread – Click for more)
https://mobile.twitter.com/_nickdavies/status/1371441682089132032
Antibody response after SARS-CoV-2 infection and implications for immunity: A rapid living review
16 Mar, 2021 | 02:30h | UTC
ACP Practice Points: What is the antibody response and role in conferring natural immunity after SARS-CoV-2 infection?
16 Mar, 2021 | 02:29h | UTC
Assessing risk for healthcare workers during the covid-19 pandemic
16 Mar, 2021 | 02:25h | UTCAssessing risk for healthcare workers during the covid-19 pandemic – The BMJ
Commentary on Twitter
NEW #BMJEducation article discusses how employers can assess risks for healthcare workers during the #COVID19 pandemic. @Azeem_Majeed @kamleshkhunti @RaoMala @CNagpaul Amanda Griffiths https://t.co/YbpZhrLsmz pic.twitter.com/e3TU56EQqH
— The BMJ (@bmj_latest) March 15, 2021
The first 12 months of COVID-19: a timeline of immunological insights
16 Mar, 2021 | 02:22h | UTCThe first 12 months of COVID-19: a timeline of immunological insights – Nature Reviews Immunology
Commentary on Twitter
We've learned a lot on the immune response and multiple discoveries throughout the covid-19 pandemic and I can't imagine it could be better summarized than by this new @NatRevImmunol paper or these authors @CyrilPedia @florian_krammer @VirusesImmunity https://t.co/6SOSP5URFf pic.twitter.com/nOCTOzmzBY
— Eric Topol (@EricTopol) March 15, 2021
Nature Series: Preparing for the next pandemic
16 Mar, 2021 | 02:19h | UTCPreparing for the next pandemic – Nature Medicine
Commentary on Twitter
Preparing for the next pandemic. A terrific collection of more than a dozen papers out today @NatureMedicine https://t.co/oQWy6q3qYs by so many of the people and labs who have guided us through the current one, including @devisridhar @gmleunghku @Baric_Lab
— Eric Topol (@EricTopol) March 15, 2021
Cartoons that explain how the COVID vaccines work
16 Mar, 2021 | 02:13h | UTCCartoons that explain how the COVID vaccines work – KevinMD
More than half of COVID-19 patients report depressive symptoms months later, study finds
16 Mar, 2021 | 02:11h | UTCOriginal study: Association of Acute Symptoms of COVID-19 and Symptoms of Depression in Adults – JAMA Network Open
Commentary on Twitter
Survey study finds 52% of individuals with prior #COVID19 met criteria for moderate or greater symptoms of depression; more likely in younger, male, and those with more severe #COVID19 @royperlis @HarvardMed @Ognyanova @RutgersU @NorthwesternU @dellavolpe https://t.co/4krNvFb29T
— JAMA Network Open (@JAMANetworkOpen) March 13, 2021
New COVID-19 risk calculator can predict severe disease or death among hospitalized patients with COVID-19
14 Mar, 2021 | 20:54h | UTCSee calculator: Severe COVID-19 Adaptive Risk Predictor (SCARP)
WHO adds Janssen vaccine to list of safe and effective emergency tools against COVID-19
14 Mar, 2021 | 20:57h | UTC
Commentary on Twitter (thread – click for more)
https://twitter.com/hildabast/status/1370537307392987141
[Preprint] RCT: Full-dose/therapeutic anticoagulation provides no benefit in critically ill patients with Covid-19
14 Mar, 2021 | 20:59h | UTCTherapeutic Anticoagulation in Critically Ill Patients with Covid-19-Preliminary Report – medRxiv
Related (results on moderately ill patients): [Not published yet] Full-dose Heparin best for moderate COVID-19 regardless of D-dimer — Data released from ACTIV-4a, ATTACC, and REMAP-CAP trials
Perspective | School reopening without robust COVID-19 mitigation risks accelerating the pandemic
14 Mar, 2021 | 20:51h | UTCSchool reopening without robust COVID-19 mitigation risks accelerating the pandemic – The Lancet
Covid vaccinations: No reason to stop using AstraZeneca jab, says WHO
14 Mar, 2021 | 20:46h | UTCCovid vaccinations: No reason to stop using AstraZeneca jab, says WHO
See also: Benefits Of AstraZeneca Vaccine Outweigh Risks, Say EMA and WHO Officials – Urging Jabs To Continue While Safety Data Around Blood Clots Is Reviewed – Health Policy Watch AND COVID-19 Vaccine AstraZeneca: PRAC investigating cases of thromboembolic events – vaccine’s benefits currently still outweigh risks – Update – European Medicines Agency AND Canada says AstraZeneca vaccine is safe after Norway and Denmark suspend use – Reuters
Urgent lessons from COVID 19: why the world needs a standing, coordinated system and sustainable financing for global research and development
14 Mar, 2021 | 20:47h | UTC
Commentary on Twitter
#COVID19 vaccines—developed, trialled, manufactured & authorised in several countries within a year. @VictorDzau et al. on lessons from the pandemic to inform an end-to-end global research & development preparedness & response ecosystem. Read https://t.co/G9PA5JBuaJ pic.twitter.com/EtFORBxvTl
— The Lancet (@TheLancet) March 12, 2021
Cohort study: Effectiveness of three vs. six feet of physical distancing for controlling spread of COVID-19 among primary and secondary students and staff
14 Mar, 2021 | 20:48h | UTC
Epidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes
14 Mar, 2021 | 20:43h | UTCEpidemiological and evolutionary considerations of SARS-CoV-2 vaccine dosing regimes – Science
Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity
14 Mar, 2021 | 20:44h | UTCMultiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity – Cell
Commentary: Vaccine-induced antibodies may be less effective against several new SARS-CoV-2 variants
Commentary on Twitter (thread – click for more)
Our paper describing the potential for mRNA vaccines to induce antibodies capable of neutralizing many of the circulating variants is now available online at Cell!https://t.co/c8B87Tg55S pic.twitter.com/eRM8ABJrQY
— Balazs Lab (@BalazsLab) March 12, 2021
Study: Healthcare settings did not increase the risk for Covid-19 infection among health care workers in the US. Exposure outside the workplace was the strongest risk factor for SARSCoV2 seropositivity
14 Mar, 2021 | 20:41h | UTCCommentaries: Healthcare settings do not increase risk for Covid-19 infection spread – University of Maryland School of Medicine AND Did Healthcare Workers Catch Covid In Or Outside The Hospital? – MedicalResearch.com AND Community Covid-19 Risk Higher Than Workplace Risk for Health Care Personnel – Physician’s Weekly
Commentary on Twitter
Cross-sectional study finds #COVID19 exposure outside the workplace was the strongest risk factor for #SARSCoV2 seropositivity. No workplace factors were associated with seropositivity. @EmoryMedicine @UMMC @HopkinsMedicine @CDCgov https://t.co/DbdSxTEb8n
— JAMA Network Open (@JAMANetworkOpen) March 10, 2021
[Press release – not published yet] Novavax reports 96% efficacy against original strain of COVID-19, 86% efficacy against B.1.1.7 variant, and 55% efficacy against B1.351 variant
12 Mar, 2021 | 08:33h | UTCPress release: Novavax Confirms High Levels of Efficacy Against Original and Variant COVID-19 Strains in United Kingdom and South Africa Trials
Commentaries: Novavax Reports Its COVID-19 Vaccine is 96% Efficacious, Based on Phase 3 Trial Results – TIME AND Novavax Says Vaccine Is 96% Effective At Preventing Original Covid-19 Virus – Forbes
Commentary on Twitter
https://twitter.com/m_scribe/status/1370126020121083913
ERS Guideline: Management of hospitalized adults with COVID-19
12 Mar, 2021 | 08:36h | UTC
NCCN Best Practices Guidance: Management of COVID-19 Infection in Patients with Cancer
12 Mar, 2021 | 08:31h | UTC
COVID-19 and liver disease: mechanistic and clinical perspectives
12 Mar, 2021 | 08:29h | UTC
Covid-19: European countries suspend use of Oxford-AstraZeneca vaccine after reports of blood clots
12 Mar, 2021 | 08:32h | UTCSee also: More European nations pause AstraZeneca vaccine use as blood clot reports investigated – CNN AND Denmark, Norway and Iceland suspend AstraZeneca COVID shots after blood clot reports – Reuters
Commentary on Twitter
Denmark has temporarily suspended use of the Oxford-AstraZeneca covid-19 vaccine as a precautionary move after reports of blood clots. But the EMA and the UK’s regulatory body say there is no indication that vaccination is linked to thromboembolic events https://t.co/sW8GRqcnLg
— The BMJ (@bmj_latest) March 11, 2021
Update to living systematic review on covid-19 in pregnancy
12 Mar, 2021 | 08:28h | UTCNews release: Update to living systematic review on covid-19 in pregnancy – The BMJ